Research Reports

Market Overview

• Global Antidepressant Drugs Market Expected to reach a high CAGR of 5.4% By 2026: DataM Intelligence
• Antidepressants are medications that can help relieve depression symptoms. The objective is to correct the chemical imbalances of neurotransmitters in the brain that are believed to be responsible for changes in behavior and mood. They can also be used to treat several other conditions, including generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and are sometimes used when treating people with chronic pains. Although antidepressants can treat the symptoms of depression, they don't address the causes, hence are typically used in combination with other therapies.

Download free sample: https://www.datamintelligence.com/download-sample/antidepressant-drugs-market

Market Dynamics

• The global market for the Antidepressant Drugs The market is primarily driven by the increase in the prevalence of depression, raising awareness regarding depression, and required clinical needs. According to WHO, depression affects 300 million people worldwide and is a common illness. Depression can become a severe health condition when long-lasting with moderate or severe intensity and can even lead to suicide. According to the WHO, there were an estimated 793,000 suicide deaths worldwide in 2016, and approximately 800,000 people die due to suicide every year. Moreover, the rising number of people suffering from stress, the emergence of novel drugs with lesser side-effects and growing elderly population, who are prone to suffer from subsyndromal depression, are expected to drive the market further. An estimated 70.9 million prescriptions for antidepressants were given in England in 2018, which has almost doubled in the past decade when compared with 36 million given out in 2008.
• However, the preference of non-pharmacological therapies over pharmacological therapies, its reduced efficacy and patent expiry of antidepressants leading to a weak pipeline may hinder market progress. 

Market Segment Analysis

• By Drug Class, the global Antidepressant Drugs market is segmented into Monoamine oxidase inhibitors, Norepinephrine-Dopamine Reuptake Inhibitor, Serotonin-norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, Tricyclic antidepressants, and others. Selective serotonin reuptake inhibitors (SSRIs) hold the most substantial market share and are the most commonly prescribed antidepressants owing to efficacy and safety. Moreover, they have fewer side effects than other antidepressants.
• By depression disorder, the global antidepressant drugs market is segmented into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. The major depressive disorder is the most prevalent as it can be caused by a combination of distress from psychological, biological, and social sources. Some significant risk factors include chronic health problems, substance abuse, family history, and drastic life changes. According to the CDC, an estimated 17.3 million adults in the US had at least one major depressive episode, which represented 7.1% of all US adults. A CDC study shows that postpartum depression estimates can be as high as 1 in 5 women in the US.

Market Geographical Analysis

• North America accounts for the largest share in the global antidepressant drugs market. This can be mainly attributed to factors the increasing prevalence of depression and government incentives to promote awareness regarding depression. According to the CDC, more than 8% of adults older than 20 reported having depression during a given two-week period in the US. According to the Anxiety Disorders Association of America, in the US, anxiety disorders are the most common mental illness affecting 40 million adults (18.1%) age 18 and older annually. Generalized anxiety disorder affects 6.8 million (3.1%) adults, panic disorder affects 6 million (2.7%) adults, and post-traumatic stress disorder affects 7.7 million (3.5%) adults, major depressive disorder affects more than 16.1 million (6.7%) the US adults, and persistent depressive disorder, also known as dysthymia, affects approximately 1.5% of the US population. Moreover, the advanced regional healthcare infrastructure, easy availability of medication, the presence of established market players, and high investment in R&D activities by them are likely to boost the North America antidepressant drugs market growth.

Market Competitive Analysis

• Companies are increasing their user base and improving their antidepressant drugs market presence by FDA approvals and investing in R&D. Moreover, several key companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to gain competitors edge in the market and also to expand its sales in the global antidepressant drugs market.
• Major Players in the global anti-depressant drugs market include Allergan plc, Pfizer Inc., Novartis AG, AstraZeneca PLC, and Johnson & Johnson.
• In May 2019, Allergan plc and Gedeon Richter Plc. announced FDA approval of supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar depression in adults. VRAYLAR is also approved in the U.S. to treat manic or mixed episodes associated with bipolar I disorder in adults.
• In March 2019, the FDA approved a Johnson & Johnson nasal spray antidepressant for people resistant to other treatments. The drug, a nasal spray called Spravato (esketamine) acts within hours, rather than weeks or months as is typical for current antidepressants.
• In March 2019, Sage Therapeutics received FDA approval for ZULRESSO (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the only specifically approved drug for the treatment of PPD, the most common medical complication of childbirth.
• In July 2018, FDA granted fast track designationfor Allergan’s investigational new treatment for the major depressive disorder - AGN-241751. AGN-241751 is a novel, oral, rapid-acting anti-depressant that recently entered Phase 2 development. 
• In July 2015, FDA approved Otsuka’s Rexulti (brexpiprazole) for the treatment of depression and schizophrenia.

Key Takeaways:

• The global market for the Antidepressant Drugs Market is primarily driven by the increase in the prevalence of depression, raising awareness regarding depression, and required clinical needs.
• Selective serotonin reuptake inhibitors (SSRIs) hold the most substantial market share and are the most commonly prescribed antidepressants owing to efficacy and safety.
• North America accounts for the dominant share in the global antidepressant drugs market. This can be mainly attributed to factors the increasing prevalence of depression and government incentives to promote awareness regarding depression.
• Companies are increasing their user base and improving their Antidepressant Drugs market presence by FDA approvals and investing in R&D. For instance, in July 2015, FDA Approved Rexulti (brexpiprazole) from Otsuka for the treatment of depression and schizophrenia.

View full report: https://www.datamintelligence.com/research-report/antidepressant-drugs-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/antidepressant-drugs-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com